Finasteride in the treatment of alopecia

Bibliography

• GISLESKOG PO, HERMANN D, HAMMARLUND-UNDENAES M, KARLSSON M: A model for the turnover of dihydrotestosterone in the presence of the irreversible 5a-reductase inhibitors GI198745 and finasteride. Clin. Pharmacol Ther. (1998) 64:636–647.
   PubMedGoogle Scholar
• CHEN W, ZOUBOULIS CC, ORFANOS CE: The 5a-reductase system and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders. Dermatology (1996) 193:177–184.
   Google Scholar
• HOFFMANN R, HAPPLE R: Finasteride is the main inhibitor of 5a-reductase activity in microdissected dermal papillae of human hair follicles. Arch. Dermatol Res. (1999) 291:100–103.
   PubMed Web of Science ®Google Scholar
• IMPERATO-McGINLEY J: 5a-metabolism in finasteride-treated subjects and male pseudohemaphrodites with inherited 5a-reductase deficiency. Eur: Um]. (1991) 20(Suppl.):78–81.
   Google Scholar
• ANDERSSON S, BERMAN DM, JENKIN EP, RUSSELL DW: Deletion of steroid 5a-reductase 2 gene in male pseudohermaphroditism. Nature (1991) 354:159–161.
   PubMed Web of Science ®Google Scholar
• COURTOIS M, LOUSSAUARN G, HOURSEAU C, GROLLIER JF: Ageing and hair cycles. Br. J. Dermatol (1995) 132:86–93.
   PubMed Web of Science ®Google Scholar
• •Good review of the hair cycle and hair growth in disease.
   Google Scholar
• GUARRERA M, REBORA A: Anagen hairs may fail to replace telogen hairs in early androgenic female alopecia. Dermatology (1996) 192:28–31.
   PubMed Web of Science ®Google Scholar
• OHTSUYAMA M, MORHASHI M: Minoxidil sulfate effect on internal calcium of cell in the epidermis and epidermal appendages. In: Hair research for the next millennium. Van Neste D, Randall V (Eds), Elsevier-Science, Amsterdam (1996):481.
   Google Scholar
• LACHGAR S, CHAVERON M, GALL Y et al.: Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br. J. Dermatol (1998) 138:407–411.
   PubMed Web of Science ®Google Scholar
• PHILIP OTT M, SANDERS D, KEALY T: Whole follicular culture. Dermatatol (1996) 14:595–607.
   Google Scholar
• MCCLELLAN KJ, MARKHAM A: Finasteride. Drugs (1999) 57(1):112–126.
   Google Scholar
• DRAKE LA, DINEHART SM, FARMER ER et al: Guidelines of care for androgenetic alopecia. J. Am. Acad. Dermatol (1996) 35:465–469.
   PubMedGoogle Scholar
• ••Seminal paper in the treatment of AGA.
   Google Scholar
• NORWOOD OT: Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg. (2001) 27:53–54.
   PubMed Web of Science ®Google Scholar
• •Important update on the prevelence of AGA in women and the population in general.
   Google Scholar
• DRAKE L, HORDINSY M, FIEDLER V et al.: The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. Am. Acad. Dermatol (1999) 41:550–554.
   PubMed Web of Science ®Google Scholar
• ••Seminal paper in the treatment of AGA.
   Google Scholar
• KAUFMAN K, OLSEN E, WHITING D et al.: Finasteride in the treatment of men with androgenetic alopecia. J. Am. Acad. Dermatol (1998) 39:578–589.
   PubMed Web of Science ®Google Scholar
• ••Seminal paper in the treatment of AGA.
   Google Scholar
• RITTMASTER RS, ANTONIAN L, NEW MI et al.: Effect of finasteride on adrenal steroidogenesis in men. .1. Andra (1994) 15:298–301.
   Google Scholar
• RITTMASTER RS, LEMAY A, ZWICKER H et al.: Effect of finasteride, a 5a-reductase inhibitor, on serum gonadotropins in normal men. J. Clin. Endocrinol Metab. (1992) 75:484–488.
   PubMed Web of Science ®Google Scholar
• Merck & Co.: Propecia® (finasteride 1 mg tablet) package insert. Merck & Co., Whitehouse Station, NJ, USA.
   Google Scholar
• GORMLEY GJ, STONER E, RITTMASTER RS et al.: Effects of finasteride (MK-906), a 5a-reductase inhibitor, on circulating androgens in male volunteers. J Clin. Endocrinol Metab. (1990) 70:1136–1141.
   PubMed Web of Science ®Google Scholar
• Merck & Co.: Proscar® (finasteride 5 mg tablet) package insert. Merck & Co., Whitehouse Station, NJ, USA.
   Google Scholar
• OVERSTREET JW, FUH VL, GOULD J et al.: Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. J. Um]. (1999) 164(4):1295–1300.
   Google Scholar
• RHODES L, HARPER J, UNO H et al: The effects of finasteride (Proscar) on hair growth, hair cycle stage, and serum testosterone and dihydrotestosterone in adult male and female stumptail macaques (Macaca arctoides). Clin. Endocrinol Metab. (1994) 79:991–996.
   Google Scholar
• PRAHALADA S, TARANTAL AF, HARRIS GS et al.: Effects of finasteride, a Type 2 5a-reductase inhibitor, on fetal development in the rhesus monkey (Macaca mulatta). Teratology (1997) 55(2):119–131.
   PubMedGoogle Scholar
• OHTAWA M, MORIKAWA H, SHIMAZAKI J: Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methy1-2-propy1)-3-oxo-4-aza-5a -androst-1-ene-173-carboxamide, a new type of specific competitive inhibitor of testosterone 5a-reductase, in volunteers. Eur. I Drug Metab. Pharmacokinet. (1991) 16:15–21.
   PubMed Web of Science ®Google Scholar
• LASSETER K: An open-label, multiple-dose study to investigate the pharmacokinetics of finasteride lmg administered orally in healthy adult male subjects. MRL clinical study report: Merck Research Laboratories. (1997), Protocol 102 [Data on file].
   Google Scholar
• SHIMAZAKI J, NOSE J: Phase I studies on MK-906, a 5a-reductase inhibitor: single dose (including food interaction) and multiple dose studies in healthy male volunteers. Yakuri To Chiryo (1990) 18(17):2675–2694.
   Google Scholar
• CARLIN JR, HOGLUND P, ERIKSSON L-0 et al: Disposition and pharmacokinetics of [14C] finasteride after oral administration in humans. Drug Metab. Dispos. (1992) 20:148–155.
   PubMed Web of Science ®Google Scholar
• STEINER J: Clinical pharmacokinetics and pharmacodynamics of finasteride. Pharmacokinet. (1996) 30(1):16–27.
   PubMed Web of Science ®Google Scholar
• GREGORIE S, WINCHELL G, CONSTANZER M et al: The effect of renal function on the disposition of finasteride, a new 5a-reductase inhibitor [abstract]. J. Clin. Pharmacol (1991) 31:859.
   Google Scholar
• GREGORIE S, WINCHELL G, CONSTANZER M et al: Multiple dose pharmacokinetics of finasteride, a 5a-reductase inhibitor in men 45–60 and 70 years old [abstract]. Pharm. Res. (1990) 7(Suppl.):S53.
   Google Scholar
• Propecia (finasteride) original NDA application clinical documentation. Merck Research Laboratories. D: clinical efficacy and safety; volume 1.23 [Data on file].
   Google Scholar
• WINCHELL GA, GREGOIRE S, TAYLOR AM et al.: Finasteride, a steroid 5a-reductase inhibitor, does not affect the oxidative metabolism of antipyrine. j Clin. Pharmacol (1993) 33:967–970.
   PubMedGoogle Scholar
• ROBERTS JL, FIEDLER V, IMPERATO-MCGINLEY J et al.: Clinical dose ranging studies with finasteride, a Type 2 5a-reductase, in men with male pattern hair loss. I Am. Acad. Dermatol.\(1999) 41:555–563.
   PubMed Web of Science ®Google Scholar
• KAUFMAN KD: Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Ear: Dermatol (2002) 12(1):38–49.
   PubMedGoogle Scholar
• ••An extension study in the treatment ofAGA in men.
   Google Scholar
• LEYDEN J, DUNLAP F, MILLER B et al: Finasteride in the treatment of men with frontal male pattern hair loss. Am. Acad. Dermatol (1999) 40:930–937.
   PubMed Web of Science ®Google Scholar
• •A primary study in the treatment of AGA of the frontal scalp (whereas others focused on vertex disease).
   Google Scholar
• VAN NEST D, FUH V, SANCHEZ-PEDRENO P: Finasteride increases anagen hair in men with androgenetic alopecia. Br. Dermatol (2000) 143(4):804–810.
   PubMedGoogle Scholar
• PRICE V, ROBERTS JL, HORINSKY M et al.: Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. Am. Acad. Dermatol (2000) 43:768–776.
   PubMed Web of Science ®Google Scholar
• LUCAS KJ: Finasteride in the treatment of hirsutism. Womens Health Gender Based Merl (1995) 4(6):655–661.
   Google Scholar
• BIRCH MP, LALLA SC, MESSENGER AG: Female pattern hair loss. Clin. Exp. Dermatol (2002) 27:383–388.
   PubMedGoogle Scholar
• OLSEN E, HORDINSKY M, ROBERTS JL, WHITING D: Female pattern hair loss. Am. Acad. Dermatol (2002) 47:795.
   PubMed Web of Science ®Google Scholar
• SHUM KW, CULLEN DR, MESSENGER AG: Hair loss in women with hyperandrogenism: four cases responding to finasteride.j Am. Acad. Dermatol (2002) 47(5):733–739.
   Google Scholar
• MOGHETTI P, CASTELLO R, MAGNANI CM et al.: Clinical and hormonal effects of the 5a-reductase inhibitor finasteride in idiopathic hirsutism. J Clin. Endocrinol. Metab. (1994)79(4):1115–1121.
   PubMedGoogle Scholar
• TOLINO A, RONSINI S, PETRONE A et al.: Finasteride in the treatment of hirsutism: new therapeutic perspectives. Steril (1996) 66(1):61–65.
   PubMedGoogle Scholar
• ERENUS M, YUCELTEN D, DURMUSOGLU F et al.: Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism. Steril (1997) 68(6):1000–1003.
   PubMed Web of Science ®Google Scholar
• FALSETTI L, DEFUSCO D, ELEFTHERIOU G et al: Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary syndrome. Gynecol. Endocrinol. (1997) 11:251–257.
   PubMed Web of Science ®Google Scholar
• WONG IL, MORRIS RS, CHANG L et al.: A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. I. Clin. Endocrinol. Metab. (1995) 80(1):233–238.
   PubMedGoogle Scholar
• BAYHAN G, BAHCECI M, DEMIRKOL T et al.: A comparative study of gonadotropin-releasing hormone agonist and finasteride on idiopathic hirsutism. Gin. Exp. ObsteL Gynecol. (2000) 27(3-4):203–206.
   PubMedGoogle Scholar
• THOMPSON IM, GOODMAN PJ, TANGEN CM et al.: The influence of finasteride on the development of prostate cancer. N EngL I Med. (2003) 349(3):297–299.
   PubMedGoogle Scholar
• SCARDINO PT: The prevention of prostate cancer - the dilemma continues. N Engl.' Med. (2003) 349(3):297–299.
   PubMedGoogle Scholar
• MAZZARELLA F, LOCONSOLE F, CAMMISA A et al.: Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16-month therapy course. Dermatol Treat. (1997) 8:189–192.
   Google Scholar
• MATSUMOTO AM, TENOVER L, MCCLUNG M et al.: The long-term effect of specific Type II 5a-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. I. Ural. (2002) 167:2105–2108.
   Google Scholar
• GREEN L, WYSOWSKI DK, FOURCROY JL: Gynecomastia and breast cancer during finasteride therapy [letter]. N. Engl. J. Med. (1996) 335(11):823.
   PubMed Web of Science ®Google Scholar
• WILTON L, PEARCE G, EDET E, FREEMANTLE S, STEPHENS MDB, MANN, RD: The safety of finasteride used in benign prostatic hypertrophy: a non-interventional observational cohort study in 14772 patients. Br. I Ural. (1996) 78:379–384.
   PubMedGoogle Scholar
• FERRANDO J, GRIMALT R: Unilateral gynecomastia induced by treatment with 1 mg of oral finasteride. Arch. Dermatol (2002) 138:543–544.
   PubMed Web of Science ®Google Scholar
• MILLER JA, PRAMANIK B, GILHOOLY P: Waxing and waning gynecomastia: an indication of noncompliant use of prescribed medication. South. Med. (1999) 92(6):615–617.
   Google Scholar
• HAAN J, HOLLANDER J, VANDUINEN S, SAXENA PR, WINTZEN AR: Reversible severe myopathy during treatment with finasteride. Muscle Nerve. (1997) 20(4):502–504.
   PubMedGoogle Scholar
• LIN Y-H, PERNG C-L, LIN H-J, CHANG F-Y: Acute pancreatitis possibly related to finasteride. I Clin. Gastroenterol (2001) 32:276.
   PubMedGoogle Scholar
• TOSTI A, PIRACCINI BM: Finasteride and the hair cycle [letter]. .1 Am. Acad. Dermatol (2000) 42(5 Pt 1):848–849.
   Google Scholar
• DIANI AR, MULHOLLAND MJ, SHULL KL et al: Hair growth effects of oral administration of finasteride, a steroid 5a-reductase inhibitor, alone and in combination with topical minoxidil in the balding stumptail macaque. I. Clin. Endocrinol Metab. (1992) 74:345-350. Affiliation James F Libecco MD & Wilma F Bergfeld MDI tAuthor for correspondence Cleveland Clinic Foundation, Department of Dermatology and Dermatopathology,9500 Euclid Ave, Cleveland, OH 44195, USA Tel: +1 440 444 5722; Fax: +1 440 445 6365; E-mail: [email protected]; [email protected]
   Google Scholar